Compare DRD & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DRD | RLAY |
|---|---|---|
| Founded | 1895 | 2015 |
| Country | South Africa | United States |
| Employees | 3410 | N/A |
| Industry | Precious Metals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.5B |
| IPO Year | N/A | 2020 |
| Metric | DRD | RLAY |
|---|---|---|
| Price | $25.92 | $13.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 10 |
| Target Price | ★ $32.63 | $19.50 |
| AVG Volume (30 Days) | 234.3K | ★ 3.8M |
| Earning Date | 08-19-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.24% | N/A |
| EPS Growth | N/A | ★ 31.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $39.23 | N/A |
| Revenue Next Year | $30.12 | $324.03 |
| P/E Ratio | $15.32 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $13.08 | $2.83 |
| 52 Week High | $39.37 | $17.32 |
| Indicator | DRD | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 38.87 | 54.25 |
| Support Level | $23.26 | $11.75 |
| Resistance Level | $30.99 | $17.32 |
| Average True Range (ATR) | 1.06 | 0.94 |
| MACD | -0.22 | 0.01 |
| Stochastic Oscillator | 5.78 | 49.61 |
DRDGold Ltd is a South African gold mining company engaged in surface gold tailings retreatment including exploration, extraction, processing, and smelting. Its reportable operating segments are; Ergo, FWGR, and Corporate office and other reconciling items. The Ergo is a surface gold retreatment operation that treats old slime dams and sand dumps to the south of Johannesburg's central business district as well as the East and Central Rand goldfields, and the FWGR which is a surface gold retreatment operation and treats old slime dams in the West Rand goldfields. The Ergo segment derives a vast majority of the company's revenue.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.